Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Erik von Willebrand.

Erik Berntorp1

  • 1Centre for Thrombosis and Haemostasis, Malmö University Hospital, Malmö, Sweden. erik.berntorp@med.lu.se

Thrombosis Research
|May 22, 2007
PubMed
Summary
This summary is machine-generated.

Von Willebrand disease, a bleeding disorder, was first described in 1926. Extensive research has since elucidated the von Willebrand factor

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Seventh Åland Island Meeting on von Willebrand Disease.

Haemophilia : the official journal of the World Federation of Hemophilia·2026
Same author

Von Willebrand disease.

Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke·2026
Same author

Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke·2026
Same author

The landmark contribution by Erik von Willebrand.

Haematologica·2026
Same author

Evaluation of kidney function and damage in patients with hemophilia B-insights from the B-Natural study.

Research and practice in thrombosis and haemostasis·2025
Same author

Mild or moderate hemophilia is not always a mild or moderate bleeding disorder: Back to the clinical phenotype.

HemaSphere·2025
Same journal

Apoptotic versus procoagulant platelets: similar "necrotic" phenotype and procoagulant activity in vitro, but distinct adhesive protein composition.

Thrombosis research·2026
Same journal

Heatstroke-induced coagulopathy: A scoping review of therapeutic strategies and outcome reporting.

Thrombosis research·2026
Same journal

Mapping thrombus habitat: Non-contrast MRI radiomics and pixel-tile histomics approach to track venous thrombosis evolution in mice.

Thrombosis research·2026
Same journal

A study protocol for a randomised controlled trial evaluating the safety and efficiency of the YEARS algorithm versus computed tomography pulmonary angiography only for suspected acute pulmonary embolism in patients with cancer: the Hydra Study.

Thrombosis research·2026
Same journal

Associating the phenotypic expression of platelets with disease type through image-based single-cell profiling.

Thrombosis research·2026
Same journal

The mechanisms of contractile dysfunction following chronic limited platelet activation in (pro)thrombotic conditions.

Thrombosis research·2026
See all related articles

Area of Science:

  • Hematology
  • Genetics
  • Molecular Biology

Background:

  • The disorder was first identified in 1926 by Finnish physician Erik von Willebrand.
  • Initial observations were made in individuals residing on the Aland islands.

Discussion:

  • Von Willebrand disease is a genetic bleeding disorder.
  • The condition is characterized by a deficiency or dysfunction of the von Willebrand factor.
  • Understanding its molecular biology is crucial for diagnosis and treatment.

Key Insights:

  • The structure and function of the von Willebrand factor are well-characterized.
  • Significant advancements have been made in understanding the molecular basis of the disease.
  • Research continues to deepen our knowledge of this complex disorder.

Related Experiment Videos

Outlook:

  • Treatment options for von Willebrand disease are continuously improving.
  • Safe and effective therapeutic products are increasingly available.
  • Future research will likely focus on personalized medicine and novel therapeutic strategies.